Literature DB >> 21677463

Cross-trial comparisons in the oncology arena: when is this justified?

Maurie Markman.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21677463     DOI： 10.1159/000324707

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


× No keyword cloud information.
  2 in total

1.  A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.

Authors:  Neal Shore; Ivan Mincik; Mark DeGuenther; Vladimir Student; Mindaugas Jievaltas; Jitka Patockova; Kelle Simpson; Chu-Hsuan Hu; Shih-Tsung Huang; Yuhua Li; Yisheng Lee; Ben Chien; John Mao
Journal:  World J Urol       Date:  2019-04-03       Impact factor: 4.226

2.  First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.

Authors:  Shaan Dudani; Jeffrey Graham; J Connor Wells; Ziad Bakouny; Sumanta K Pal; Nazli Dizman; Frede Donskov; Camillo Porta; Guillermo de Velasco; Aaron Hansen; Marco Iafolla; Benoit Beuselinck; Ulka N Vaishampayan; Lori A Wood; Elizabeth Liow; Flora Yan; Takeshi Yuasa; Georg A Bjarnason; Toni K Choueiri; Daniel Y C Heng
Journal:  Eur Urol       Date:  2019-08-22       Impact factor: 20.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.